LUC7L

Across TCGA pan-cancer cohorts, LUC7L RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of LUC7L’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where LUC7L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LUC7L is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

COAD, LIHC, and STAD are the cancer types where LUC7L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LUC7L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	All	IV	+1.081	<.001	10	view →
LIHC	Female	II,III,IV	+1.021	<.001	9	view →
STAD	All	II,III,IV	+0.614	.002	7	view →
CHOL	Male	All	+2.598	<.001	5	view →
KIRP	All	IV	+1.332	.011	5	view →
READ	All	All	+1.020	<.001	5	view →
KIRC	All	All	+0.268	<.001	4	view →
KICH	All	All	−0.578	<.001	3	view →
HNSC	All	All	+0.273	.030	2	view →
LUAD	Female	All	+0.349	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

LUC7L–COAD

Open the COAD breakdown →